Goldman Sachs Reports 1.02M Shares (6.1%) of Agilon

The Goldman Sachs Group, Inc. filed a Schedule 13G disclosing shared beneficial ownership of 1,018,303.08 shares of Agilon Health, Inc. common stock as of 03/31/2026.

Rhea-AI Filing Summary

The Goldman Sachs Group, Inc. filed a Schedule 13G disclosing shared beneficial ownership of 1,018,303.08 shares of Agilon Health, Inc. common stock as of 03/31/2026. The filing shows shared voting and shared dispositive power of 1,018,278.08 and 1,018,303.08 respectively, representing 6.1% of the class. The filing is a joint submission with Goldman Sachs & Co. LLC and includes exhibit disclosures identifying the reporting subsidiary and the joint filing agreement.

Insights

Institutional Ownership Analyst

Large passive stake disclosed by Goldman Sachs reporting units.

The filing reports 1,018,303.08 shares held in aggregate by Goldman Sachs reporting units, equal to 6.1% of Agilon Health's common stock as of 03/31/2026. The amounts are shown as shared voting and shared dispositive powers.

This Schedule 13G indicates an ownership disclosure under passive/investment manager reporting; the filing includes a joint filing agreement and exhibits describing the subsidiary relationship. Subsequent filings may state any material changes in ownership or voting status.

Key Figures

Reporting date: 03/31/2026 Shares beneficially owned: 1,018,303.08 shares Shared voting power: 1,018,278.08 shares +3 more

6 metrics

Reporting date 03/31/2026 Beneficial ownership as of this date

Shares beneficially owned 1,018,303.08 shares Aggregate reported by Goldman Sachs reporting units

Shared voting power 1,018,278.08 shares Shared power to vote as shown on cover page

Shared dispositive power 1,018,303.08 shares Shared power to dispose as shown on cover page

Percentage of class 6.1% Percent of outstanding common stock reported

CUSIP 00857U206 Agilon Health common stock identifier

Key Terms

Schedule 13G, Shared dispositive power, Parent holding company

3 terms

Schedule 13G regulatory

"filed a Schedule 13G disclosing shared beneficial ownership"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Shared dispositive power regulatory

"Shared Dispositive Power 1,018,303.08"

Parent holding company regulatory

"The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group") as a parent holding company"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Goldman Sachs report in AGL?

Goldman Sachs reports beneficial ownership of 1,018,303.08 shares, equal to 6.1% of Agilon Health common stock as of 03/31/2026. The filing lists the same figure for shared dispositive power and reflects joint filing with Goldman Sachs & Co. LLC.

What voting or dispositive power is disclosed on the Schedule 13G?

The filing shows shared voting power of 1,018,278.08 shares and shared dispositive power of 1,018,303.08 shares. Sole voting and sole dispositive powers are reported as zero in the cover data provided.

Does this Schedule 13G indicate active control or a passive position?

This Schedule 13G is filed under passive/investment manager reporting conventions and therefore reflects a disclosed passive reporting position. The exhibits identify a parent-subsidiary reporting relationship for the Goldman Sachs reporting units.

Which entities filed the joint Schedule 13G for Agilon Health (AGL)?

The joint filing parties are The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC, with a signed joint filing agreement and exhibits identifying the reporting subsidiary and filing units.

What CUSIP and date are associated with this filing?

The CUSIP reported is 00857U206 and the ownership amounts are stated as of 03/31/2026. The signature pages in the excerpt are dated 04/24/2026 for the joint filing agreement exhibit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 10:28 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

AGILON HEALTH, INC.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

00857U206

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 00857U206

1

Names of Reporting Persons

THE GOLDMAN SACHS GROUP, INC.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,018,278.08
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,018,303.08

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,018,303.08

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP Number(s): 00857U206

1

Names of Reporting Persons

GOLDMAN SACHS & CO. LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,018,278.08
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,018,303.08

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,018,303.08

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

BD, OO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AGILON HEALTH, INC.
(b)	Address of issuer's principal executive offices: 440 POLARIS PARKWAY,SUITE 550,WESTERVILLE,X1,43082
Item 2.
(a)	Name of person filing: THE GOLDMAN SACHS GROUP, INC.| GOLDMAN SACHS & CO. LLC
(b)	Address or principal business office or, if none, residence: The Goldman Sachs Group, Inc. 200 West Street New York, NY 10282| Goldman Sachs & Co. LLC 200 West Street New York, NY 10282
(c)	Citizenship: THE GOLDMAN SACHS GROUP, INC. - Delaware| GOLDMAN SACHS & CO. LLC - New York
(d)	Title of class of securities: Common Stock, par value $0.01 per share
(e)	CUSIP Number(s): 00857U206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: See the response(s)to Item 11 on the attached cover page(s).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit (99.2)
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

THE GOLDMAN SACHS GROUP, INC.

Signature:	Name: Veronica Mupazviriwo
Name/Title:	Attorney-in-fact
Date:	04/24/2026

GOLDMAN SACHS & CO. LLC

Signature:	Name: Veronica Mupazviriwo
Name/Title:	Attorney-in-fact
Date:	04/24/2026

Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.01 per share, of AGILON HEALTH, INC. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 04/24/2026 THE GOLDMAN SACHS GROUP, INC. By:/s/ Veronica Mupazviriwo ---------------------------------------- Name: Veronica Mupazviriwo Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ Veronica Mupazviriwo ---------------------------------------- Name: Veronica Mupazviriwo Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group. EXHIBIT (99.3) ITEM 4 INFORMATION *In accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned by certain operating units (collectively, the "Goldman Sachs Reporting Units") of The Goldman Sachs Group, Inc. and its subsidiaries and affiliates (collectively, "GSG"). This filing does not reflect securities, if any, beneficially owned by any operating units of GSG whose ownership of securities is disaggregated from that of the Goldman Sachs Reporting Units in accordance with the Release. The Goldman Sachs Reporting Units disclaim beneficial ownership of the securities beneficially owned by (i) any client accounts with respect to which the Goldman Sachs Reporting Units or their employees have voting or investment discretion or both, or with respect to which there are limits on their voting or investment authority or both and (ii) certain investment entities of which the Goldman Sachs Reporting Units act as the general partner, managing general partner or other manager, to the extent interests in such entities are held by persons other than the Goldman Sachs Reporting Units.